In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 54 for your search:

Drug:  etoposide phosphate
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors

Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-00055-18, NCT00415103

Bevacizumab in Extensive Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-0802, 2009-010187-42, NCT00930891

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560

Phase III Randomized Study of Sequential High-Dose Ifosfamide, Carboplatin, and Etoposide Phosphate Followed By Autologous Peripheral Blood Stem Cell or Bone Marrow Transplantation Versus Standard Ifosfamide, Carboplatin, and Etoposide in Patients With Limited or Extensive Stage Small Cell Lung Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 65 and under
Sponsor: Other
Protocol IDs: EBMT-RANDOM-ICE, EU-98001, NCI-V01-1645, NCT00011921

Phase III Study of Neoadjuvant Chemotherapy in Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Blood Stem Cell Support. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 1
Sponsor: Other
Protocol IDs: CCLG-NB-1999-03, EU-20597, NCT00417053

Phase III Study of Combination Chemotherapy Comprising Carboplatin or Cisplatin, Etoposide Phosphate, and Ifosfamide and Radiotherapy in Patients With Intracranial Germ Cell Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: CCLG-GC-1997-01, EU-20579, SIOP-CNS-GCT-96, NCT00293358

Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000531141, CRUK-LUNGSTAR, EU-20649, ISRCTN56306957, EUDRACT-2005-005821-71, UCL-BRD/05/129, MREC-06-MRE10-28, CTA-20363-0215-001, CTAAC-C1312-A5335, CTAAC-C1312-A12462, NCT00433498

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: D0750018, NCT00660504

Further Retrospect Clinical Study for FDA IND Exemption - Etoposide and Single Nucleotide Polymorphisms

Phase: Phase III
Type: Biomarker/Laboratory analysis
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: FWA00015357, NPI - 1831468511, NPI - 1023387701, NCI CTEP ID - MD153, NCI Investigator ID - 49256, NCT01064466

10.

Phase I/II Study of Topotecan as a Component of Multicourse High Dose Chemotherapy with Peripheral Blood Stem Cell Support in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CPMC-IRB-7866, NCI-G97-1327, NCT00003064

11.

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 15 to 69
Sponsor: Other
Protocol IDs: 11752, MCC-11752, IRB-4983, NCI-G00-1749, MCC-IRB-4983, NCT00005792

12.

A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLO21800205, NCT00315705

13.

Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: PSHCI 08-005, NCT00702962

14.

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 07053, P30CA033572, CHNMC-07053, CA180 121, CDR0000617760, NCT00788125

15.

GCS-100 in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PR-CS010, NCT00776802

16.

A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060534, NCT00791154

17.

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CWRU4196, P30CA043703, BMS-CRWU-4196, NCI-G00-1854, NCT00006260

18.

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 30 and under at original diagnosis
Sponsor: NCI, Other
Protocol IDs: CDR0000068681, COG-ANBL00P1, NCT00017368

19.

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000276590, U10CA021115, E5501, ECOG-5501, NCT00057837

20.

Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: Other
Protocol IDs: CNS 0294, NCT00179920

21.

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: INST 1003C, NCT00250718

22.

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: CDR0000466167, CALGB-50403, NCT00310037

23.

Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 64 and under
Sponsor: Other
Protocol IDs: AMC 2005-276, NCT00336843

24.

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CG53135-CLN-12, NCT00323518

25.

ALL Adult Consortium Trial: Adult ALL Trial

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 50
Sponsor: Other
Protocol IDs: 06-254, NCT00476190

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map